Fisher Asset Management LLC Has $5.33 Million Holdings in West Pharmaceutical Services, Inc. $WST

Fisher Asset Management LLC lessened its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 17.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,338 shares of the medical instruments supplier’s stock after selling 4,983 shares during the quarter. Fisher Asset Management LLC’s holdings in West Pharmaceutical Services were worth $5,325,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Zions Bancorporation National Association UT bought a new stake in West Pharmaceutical Services during the 1st quarter worth about $25,000. Quarry LP bought a new stake in West Pharmaceutical Services during the first quarter worth about $27,000. Vermillion & White Wealth Management Group LLC boosted its position in West Pharmaceutical Services by 193.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 95 shares during the last quarter. CVA Family Office LLC grew its stake in West Pharmaceutical Services by 573.3% in the second quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock valued at $44,000 after purchasing an additional 172 shares in the last quarter. Finally, Cromwell Holdings LLC increased its position in shares of West Pharmaceutical Services by 587.5% during the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 188 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on WST shares. Evercore ISI increased their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “outperform” rating in a report on Thursday, October 23rd. Rothschild Redb upgraded shares of West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, September 15th. Zacks Research downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Tuesday, October 14th. Finally, Morgan Stanley initiated coverage on shares of West Pharmaceutical Services in a research note on Monday. They issued an “equal weight” rating and a $285.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, West Pharmaceutical Services currently has a consensus rating of “Moderate Buy” and a consensus price target of $343.36.

West Pharmaceutical Services Stock Down 1.0%

Shares of WST opened at $281.42 on Friday. The firm has a market cap of $20.24 billion, a P/E ratio of 41.69, a price-to-earnings-growth ratio of 4.39 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.18 and a current ratio of 2.87. West Pharmaceutical Services, Inc. has a 52 week low of $187.43 and a 52 week high of $348.90. The firm’s 50-day simple moving average is $273.34 and its 200 day simple moving average is $247.37.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. The company had revenue of $804.60 million during the quarter, compared to analysts’ expectations of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The business’s revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.85 earnings per share. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. On average, analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.